 |
 |
 |
 |
||
 |
 On-Q-ity Waltham, MA, MA On-Q-ity is a second generation diagnostics company transforming cancer treatment through non-invasive diagnostics and monitoring. The company is focused on offering oncologists and their patients more cost-effective, informative and actionable treatment guidance through innovative diagnostics that identify the unique characteristics of an individual's cancer, predict the response to therapy, and monitor the efficacy of treatment. On-Q-ity leverages two core technologies: DNA repair pathway biomarkers to predict treatment response in tissue and blood and microfluidic chip technology to capture, enumerate, and molecularly characterize circulating tumor cells (CTC) from a sample of blood. The company's CTC and biomarker technologies originated from groundbreaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively. Founded in May 2009 |
|
 
      
|
||